secwatch.observer — SEC 8-K summary
======================================

Issuer:     Akili, Inc. (—)
CIK:        0001850266
Form:       8-K
Filed at:   2023-01-12T23:59:59+00:00
Accession:  0001193125-23-006912
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 2.05, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Akili cuts workforce 30%, pauses adult ADHD trial, extends cash runway to Q1 2025
--------------------------------------------------------------------------------

- Workforce reduced ~30% (46 employees); severance costs estimated $1.5-2.5M recorded in Q1 2023.
- Pivotal adult ADHD trial (AKL-T01) enrollment stopped with 224 patients; data analysis ahead of schedule.
- Company projects 2023 non-GAAP total operating expenses of $55-60M, excluding stock-based comp.
- Cash runway extended to fund operations into Q1 2025.
- Pipeline reprioritized: focus on commercial EndeavorRx; ASD, MS, MDD Q-Sub meetings not pursued to conserve cash.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1850266/000119312523006912/0001193125-23-006912-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1850266/000119312523006912/d422648d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-006912

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer